Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
adults were using GLP-1 drugs for weight loss in late 2025, reflecting the strong real-world results these medications produce
Frequency: Once per day (subcutaneous) during loading phase
May be more useful info in pinned post "Various B12D/PA resources" on right of screen if on computer
We are in England I have a 20 year old daughter who is a dance student and has had to pull out of her course due to hip Labral tear pain and also has snapping hit
Insulin Sensitivity and Beta Cell Function Research revealed improvements in both insulin sensitivity and pancreatic function[13]: Enhanced HOMA-IR scores indicating improved insulin sensitivity Reduced fasting insulin levels despite improved glucose control Preserved or improved beta cell function markers (HOMA-beta, C-peptide) Potential protective effects on pancreatic beta cell mass in preclinical models Cardiovascular and Metabolic Health Research Lipid Profile Improvements Studies documented favorable effects on multiple cardiovascular risk markers[14]: LDL cholesterol reductions of 15-20% observed with GLP3 Triglyceride reductions of 20-30% documented across studies Improved HDL cholesterol levels in some study populations Potential PCSK9 degradation effects through glucagon receptor activation Blood Pressure and Heart Rate Effects Cardiovascular monitoring in clinical trials revealed consistent patterns[15]: Systolic blood pressure reductions of 5-10 mmHg observed with weight loss Diastolic pressure improvements of 3-5 mmHg documented Dose-dependent heart rate increases (5-10 bpm) that peaked at 24 weeks then declined Heart rate changes similar to other GLP-1 receptor agonists Hepatic Steatosis and Liver Health Research Liver Fat Reduction Studies Research in metabolic dysfunction-associated steatotic liver disease (MASLD) models showed remarkable effects[16]: GLP3 achieved 82% relative liver fat reduction after 48 weeks in phase 2a MASLD trials Over 85% of participants achieved resolution of MASLD (liver fat below 5%) Improvements in liver enzymes (ALT, AST) and fibrosis biomarkers documented Potential anti-fibrotic effects through multiple pathway modulation The glucagon receptor component appears particularly relevant for liver fat reduction, as the liver is rich in glucagon receptors but lacks GLP-1 receptors
